A Proof-of-Concept Study of Ulipristal Acetate for Early Medication Abortion
This study suggests that ulipristal acetate followed by misoprostol is an effective and acceptable medication abortion regimen with no reported serious adverse events. (This project is supported by the OPTions Initiative. The study registered as ISRCTN35625202.).
Authors
- Ilana G. Dzuba
- Manuel Bousiéguez (ORCID: https://orcid.org/0000-0002-6511-2236)
- Jorge Salmerón (ORCID: https://orcid.org/0000-0002-5113-299X)
- Karina Robles-Rivera (ORCID: https://orcid.org/0009-0005-3920-5980)
- Sonia Hernández-Salazar (ORCID: https://orcid.org/0000-0001-7307-4308)
- María García‐Martínez (ORCID: https://orcid.org/0009-0004-5422-1842)
- Beverly Winikoff
- Angélica Martínez-Huitrón
- Lucía Aguirre-Antonio
Institutions
- Gynuity Health Projects (US)
- MSD (Mexico) (MX)
- Universidad Nacional Autónoma de México (MX)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2025-01-23
- DOI
- https://doi.org/10.1056/evidoa2400209
- Citations
- 8
- Primary Topic
- Reproductive Health and Contraception
- Type
- article
- Field-Weighted Citation Impact
- 15.03